# Study of GSK1363089 in Metastatic Gastric Cancer

> **NCT00725712** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 74 (actual)

## Conditions studied

- Neoplasms, Gastrointestinal Tract

## Interventions

- **DRUG:** GSK1363089 (formerly XL880)

## Key facts

- **NCT ID:** NCT00725712
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03-31
- **Primary completion:** 2009-11-01
- **Final completion:** 2009-11-30
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00725712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00725712, "Study of GSK1363089 in Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00725712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*